Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies
Annals of Pancreatic Cancer · 2026-08 · 9 · 21-21
DOI: 10.21037/apc-26-0014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pancreatic Cancer, 2026-08. Verfasst von Ahmed Abdelhakeem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
administration achieved an mOS of 14 months compared to 8.8 months in low expanders
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
ORCID-Profile: Hani M Babiker
Förderung
- NCI NIH HHS
Zitieren
APA
Abdelhakeem, A., & Babiker, H. M. (2026). Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies. Annals of Pancreatic Cancer, 9, 21-21. https://doi.org/10.21037/apc-26-0014
Vancouver
Abdelhakeem A, Babiker HM. Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies. Annals of Pancreatic Cancer. 2026;9:21-21. doi:10.21037/apc-26-0014
BibTeX
@article{Abdelhakeem2026,
author = {Abdelhakeem, Ahmed and Babiker, Hani M},
title = {Precision immunotherapy in metastatic pancreatic cancer: OPTIMIZE-1 biomarker-driven patient stratification for future studies},
journal = {Annals of Pancreatic Cancer},
year = {2026},
volume = {9},
pages = {21--21},
doi = {10.21037/apc-26-0014}
}
EUVIMED